2. Search Result
Search Result
Results for "

Cyclind Inhibitors

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Peptides

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112272
    Lerociclib
    2 Publications Verification

    G1T38

    		 CDK Cancer
    Lerociclib (G1T38) is a potent and selective inhibitor of CDK4/6, with IC50s of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.
    Lerociclib
  • HY-112272A
    Lerociclib dihydrochloride
    2 Publications Verification

    G1T38 dihydrochloride

    		 CDK Cancer
    Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 1 nM and 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.
    Lerociclib dihydrochloride
  • HY-126251
    CDK9-IN-7

    		CDK Apoptosis Cancer
    CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC .
    CDK9-IN-7
  • HY-13338
    Mabuterol

    		Adrenergic Receptor Cardiovascular Disease
    Mabuterol is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB .
    Mabuterol
  • HY-170992
    Autophagy agonist-1

    		Autophagy CDK Atg8/LC3 PINK1/Parkin Cancer
    Autophagy agonist-1 (compound 22) is an Autophagy agonist. Autophagy agonist-1 exhibits significant anticancer activity against HepG2 cells and normal cells with IC50s of 8.8 μM and > 50 μM. Autophagy agonist-1 induces G1/S phase cell cycle arrest and inhibits CDK4 and CyclinD1 expression while upregulating P21. Autophagy agonist-1 promotes the accumulation of autophagosomes and the proteins LC3 and PINK1, enhancing autophagy and mitophagy in HepG2 cells .
    Autophagy agonist-1
  • HY-113770
    Lysyl threonine

    Lys-Thr

    		 Drug Intermediate Cancer
    Lysyl threonine (Lys-Thr) is a dipeptide. Lysyl threonine can be used to synthesize the pentapeptide Gly-Thr-Gly-Lys-Thr. Gly-Thr-Gly-Lys-Thr confers cell sensitivity to anticancer agents by inhibiting the binding of CAGE to GSK3β and reducing the expression of CyclinD1 .
    Lysyl threonine
  • HY-124398
    GL-1196

    		PAK Cancer
    GL-1196 is an inhibitor of PAK4. GL-1196 can suppress the proliferation and invasion of gastric cancer cells. GL-1196 inhibits PAK4-mediated signaling pathways. GL-1196 can hinder the proliferation of human gastric cancer cells through suppressing PAK4/c-Src/EGFR/CyclinD1 and CDK4/6. GL-1196 can reduce filamentous pseudopodia formation and induce filamentous pseudopodia formation and promote cell elongation in SGC7901 and BGC823 cells. GL-1196 can be studied in anti-cancer research .
    GL-1196
  • HY-155180
    FD2056

    		PI3K Cancer
    FD2056 is a potent and orally active PI3K inhibitor. FD2056 inhibits PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ with IC50s of 0.30, 0.80, 1.10, 0.42 nM. FD2056 also inhibits CDK2-CyclinA2 and CDK4-CyclinD3 with IC50 of 115.95 and 2782.15 nM. FD2056 inhibits breast cancer cell proliferation with IC50s of 1.06, 0.04, 1.40 μM for MDA-MB-231, MDA-MB-468, MCF-7 cells. FD2056 also induces cancer apoptosis and inhibits tumor growth .
    FD2056
  • HY-W755295
    Mabuterol hydrochloride

    		Adrenergic Receptor Cardiovascular Disease
    Mabuterol hydrochloride is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol hydrochloride inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol hydrochloride suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB .
    Mabuterol hydrochloride
  • HY-152051S
    Mabuterol-d9 hydrochloride

    		Isotope-Labeled Compounds Adrenergic Receptor Cardiovascular Disease
    Mabuterol-d9 (hydrochloride) is deuterium labeled Mabuterol (hydrochloride). Mabuterol hydrochloride is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol hydrochloride inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol hydrochloride suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB .
    Mabuterol-d9 hydrochloride
  • HY-13338R
    Mabuterol (Standard)

    		Adrenergic Receptor Reference Standards Cardiovascular Disease
    Mabuterol (Standard) is the analytical standard of Mabuterol. This product is intended for research and analytical applications. Mabuterol is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB .
    Mabuterol (Standard)
  • HY-W755295R
    Mabuterol hydrochloride (Standard)

    		Reference Standards Adrenergic Receptor Cardiovascular Disease
    Mabuterol (hydrochloride) (Standard) is the analytical standard of Mabuterol (hydrochloride). This product is intended for research and analytical applications. Mabuterol hydrochloride is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol hydrochloride inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol hydrochloride suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB .
    Mabuterol hydrochloride (Standard)
  • HY-123238
    AG-024104

    		CDK Cancer
    AG-024104 is a CDK inhibitor with Ki values of 2.3 nM (CDK1/cyclinB), 1.8 nM (CDK2/cyclinA), and 0.67 nM (CDK4/cyclinD). AG-024104 functionally inhibits kinase activity of CDK1/cyclinB, CDK2/cyclinA, and CDK4/cyclinD. AG-024104 serves as a negative control for peripheral leukocyte toxicity studies in preclinical development .
    AG-024104
  • HY-183297
    CDK4-IN-5

    		CDK Cancer
    CDK4-IN-5 is a potent, orally active and selective CDK4 inhibitor. CDK4-IN-5 suppresses CDK4 expression and downregulates the CDK4/CyclinD1 complex. CDK4-IN-5 induces G0/G1 phase cell cycle arrest in bladder cancer cells via CyclinD1 expression suppression. CDK4-IN-5 selectively exerts activity against bladder cancer cells. CDK4-IN-5 can be used for the research of bladder cancer .
    CDK4-IN-5
  • HY-181514
    STAT3-IN-53

    		STAT CDK c-Myc Apoptosis Cancer
    STAT3-IN-53 (Compound L20) is a STAT3 inhibitor with a Kd value of 6.16 μM. STAT3-IN-53 binds directly to the SH2 domain of STAT3, inhibits phosphorylation at the Y705 site without affecting the total STAT3 protein level, and suppresses the IL-6/JAK/STAT3 pathway. STAT3-IN-53 downregulates the transcription and expression of cyclin-D1 and c-Myc. STAT3-IN-53 induces cell cycle arrest and promotes Apoptosis. STAT3-IN-53 exhibits anticancer activity against colorectal cancer .
    STAT3-IN-53

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: